- News & Features
Some psoriatic arthritis patients may be able to take a common TNF inhibitor drug less frequently and still maintain remission.
Researchers found an association between obesity and less effectiveness of tumour necrosis factor inhibitors (TNFi).
Extended study reinforces the importance of early interventions for rheumatoid arthritis.
The disease-modifying anti-rheumatic drug methotrexate, the first line of defense against rheumatoid arthritis symptoms, is administered as a weekly pill or a shot. Many patients find it helps keep their symptoms under control for years, but up to a quarter...
Asking your doctor is among the best ways to find out about new treatments and clinical trials.
The introduction of biologic disease-modifying anti-rheumatic drugs are associated with a decrease in total knee replacements among RA patients.
Rheumatoid arthritis patients who take opioids or antidepressants are likelier to fracture their bones, according to research presented at the 2017 American College of Rheumatology annual meeting in San Diego.
“The results of this preliminary study may help rheumatologists to differentiate RA patients who would successfully down-titrate biologics”
Treat-to-target, evidence-based guidelines recommend that rheumatoid arthritis patients be monitored regularly for disease activity.
Patients with longstanding rheumatoid arthritis, called refractory, who had been treated with tumor necrosis factor inhibitors (TNFis), saw improvements after a year of taking rituximab (Rituxan). That’s according to an analysis from the Corrona RA registry, which was published in...
On July 27, German pharmaceutical company Boehringer Ingelheim announced it had enrolled the first patient in a study intended to demonstrate that a biosimilar is interchangeable with Humira (adalimumab) for treating patients with moderate-to-severe chronic plaque psoriasis. Ivan Blanarik, Boehringer Ingelheim’s...